Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review
5 hours ago
- #real-world study
- #satralizumab
- #neuromyelitis optica spectrum disorder
- Study evaluates the long-term effectiveness and safety of satralizumab in Japanese patients with AQP4[+] NMOSD over 2.5 years.
- 124 patients were analyzed, showing a significant decrease in annualized relapse rate (ARR) from 0.45 to 0.03 after 130 weeks of treatment.
- 91.8% of patients remained relapse-free at 130 weeks, with 48.8% of these patients no longer requiring oral glucocorticoids (GCs).
- Reduction in concomitant medications observed: 80.0% stopped azathioprine (AZA) and 47.1% stopped tacrolimus (TAC) by 130 weeks.
- Serious drug reactions occurred in 9.7% of patients, with serious infections being the most common at 6.5%.
- The study supports satralizumab's relapse-preventive effect in AQP4[+] NMOSD without new safety concerns.